Rapid Communications 3: Pituitary and Neuroendocrinology 1

ea0090rc3.1 | Rapid Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

Abstract withdrawn...

0 shares

ea0090rc3.2 | Rapid Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

Increased intracellular and extracellular myocardial mass on cardiac magnetic resonance imaging in patients with acromegaly

Wolf Peter , Bouazizi Khaoula , Kachenoura Nadjia , Piedvache Celine , Gallo Antonio , Salenave Sylvie , Maione Luigi , Young Jacques , Prigent Mikael , Lecoq Anne-Lise , Kuhn Emmanuelle , Agostini Helene , Trabado Severine , Redheuil Alban , Chanson Philippe , Kamenicky Peter

Background: Acromegaly is associated with an increased left ventricular mass, as reported in echo-based and more recently in few cardiac MRI studies. One possible explanation of this increased ventricular mass could be water retention and consequently edema of the ventricular wall.Methods: In this prospective, cross-sectional study 26 patients with active acromegaly and 31 control subjects of comparable age and sex were investigated by cardiac MRI. Patie...

0 shares

ea0090rc3.3 | Rapid Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

The spectrum of cardiac disease in patients with acromegaly: results from the SUM trial

De Alcubierre Dario , Feola Tiziana , Cozzolino Alessia , Pofi Riccardo , Pirchio Rosa , Galea Nicola , Cristina De Martino Maria , Pivonello Rosario , Isidori Andrea , Giannetta Elisa

Introduction: Cardiac abnormalities are common in patients with acromegaly and contribute to the increased morbidity and mortality of the disease. Cardiac magnetic resonance (CMR) is the established, non-invasive gold standard for measuring morpho-functional changes of the heart. We aimed to detect cardiac alterations in patients with acromegaly through CMR and to identify potential risk factors associated with cardiac impairment.Materials and methods: T...

0 shares

ea0090rc3.4 | Rapid Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

SGLT2 Inhibitors in a case series of diabetic acromegaly patients: Effects beyond diabetes

Melin Uygur Meliha , Abbasgholizadeh Anna

Objective: There has been no consensus on the medical management of diabetes in acromegaly patients. The primary approach is like the general population, and metformin is considered first-line therapy. Sodium-glucose cotransporter inhibitors (SGLT2is) are a novel antidiabetic class which has an improving effect on insulin resistance. There is no recommendation regarding their use for diabetic acromegaly patients despite their potential beneficial effects by inducing glucosuria...

0 shares

ea0090rc3.5 | Rapid Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

The Reassessment of Therapeutic Decisions by Clinicians According to the SAGIT® Instrument in Acromegaly: Results of a Multicenter Study

Turgut Seda , Ciftci Sema , Yilmaz Nusret , Uysal Serhat , Muradov İlkin , Kılıc Kan Elif , Cansu Guven Baris , Yenidunya Yalın Gulşah , Uc Ziynet ALphan , Sarıbeyliler Goktuğ , Pehlivan Esma , Bagir Gulay Simsek , Tanrikulu Seher , Yaylali Guzin , Mısıroğlu Fuat , Omma Tulay , Selcukbiricik Ozlem Soyluk , Cakir İlkay , Yurekli Banu Sarer , Ertorer Melek Eda , Kadioglu Pinar , Saygili Fusun , Yarman Sema

Objective: SAGIT, a new instrument designed for therapeutic decision, is not routinely used yet. While the medical treatment was mostly planned according to disease activity by hormonal evaluation, the therapeutic decision has tried to be standardized with the SAGIT instrument. The aim of this study is to reassess the therapeutic decisions by clinicians in the management of acromegaly according to the SAGIT instrument.Material and Method: This multicente...

3 shares

ea0090rc3.6 | Rapid Communications 3: Pituitary and Neuroendocrinology 1 | ECE2023

Discontinuation of long-term growth hormone treatment in adults with severe growth hormone deficiency: A United Kingdom web-based survey of endocrine practice

Criseno Sherwin , Gleeson Helena , Toogood Andrew , Gittoes Neil , Topping Annie , Karavitaki Niki

Introduction: In adults, treatment of growth hormone deficiency (GHD) with daily recombinant human growth hormone (GH) injections has shown to improve many clinical features associated with GHD. Currently, many adults with GHD receive GH indefinitely, even when they fail to report any obvious benefits from this treatment. Additionally, evidence on the impact of discontinuing long-term GH therapy is limited. We conducted a survey of UK endocrine clinicians (doctors and speciali...

0 shares

Endocrine Abstracts

25th European Congress of Endocrinology